Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
